Sat Kartar Life Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8t7sxtmvt3e88w8cz4vzdgby.pdf

Key Takeaways


The Dual-Engine Shift: Product Company Plus Hospitals

Manprit Singh Chadha: “We were a product company, categorized as a product company. We will definitely remain as a product company primarily, but yes, are moving into a whole fledged ecosystem, into the complete sphere of the healthcare of Ayurveda.”

The Jeena Sikho Partnership

Manprit Singh Chadha: “Why would I actually try to invest more in North India, rather than invest in South India and take the expertise and why to reinvent the wheel? Why not let the wheel move forward to South India?”

Revenue Build-Up and Targets

Manprit Singh Chadha: “200 is achieved, 300 and 500 plus must be achieved!”

Margins, Cash and Working Capital

Manprit Singh Chadha: “If cash is not generated, my difference between which has never been the EBITDA to PAT, is going to get screwed.”

AI, Repeat Patients and Operating Levers


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetCross ₹300 cr (product business only, excludes hospitals)FY27
Revenue targetCross ₹500 cr (product business only, excludes hospitals)FY28
Hospital break-evenDelhi 30-bed facility breaks evenEnd of May or June 2026
Hospital bed capacity300 beds under Sat Kartar fold (150–200 via Jeena Sikho management)FY27 end
Hospital bed capacity1,000 bedsFY28
PAT margin11–12% on product businessFY27 (on ₹300 cr base)
Blended margin18–20% (product + hospital)H1 FY28
Subsidiary revenue₹25–30 cr from subsidiariesFY27
US subsidiaryOperations begin; RBI approval pending (~30 days)Operations can start before equity subscription
Hospital location finalisationIdentify and finalise locations for next facilitiesBy June 2026

Key Metrics

MetricQ4 FY26
Revenue₹200+ cr (FY26), +23% YoY
EBITDA growth+73% (FY26)
PAT₹17 cr (FY26), +74% YoY
PAT margin8.5% to 9% (FY26), up from 6% in FY25
FY27 revenue guidance₹300 cr, excluding hospital revenue
FY28 revenue guidance₹500 cr, excluding hospital revenue
FY27 PAT margin target11% to 12%
Advertisement spend40% of revenue, nothing capitalized
Average ticket size₹3,250, crossed from ₹3,100; targeting ₹3,500
Repeat patient rate25% to 26%
Subsidiary revenue₹1.2 cr (FY26); FY27 target ₹25–30 cr
Hospital beds operational30 beds (Delhi), running for 40 days
Hospital utilizationNot crossed 10%
Hospital daily revenue~₹50,000, against breakeven of ₹1L per day
Hospital ARPOB target₹10,000+ per bed per day
Hospital margin at 60% occupancy30% to 35%
Blended PAT margin target (H1 FY28)18% to 20%, including hospital revenue
Cash balance for hospital expansion₹45 cr
AI-driven ROI improvement4% to 5% better ROI in trials